Compare Inovio Pharmaceuticals Inc (INO) vs Global X Uranium ETF (URA) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

URA trades at $38.64, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages but oversold RSI signals. The ETF holds $6.29 billion in assets and benefits from strong narratives around AI-driven power demand and nuclear energy expansion, though key financial ratios are not publicly detailed for the fund itself. Recent news highlights uranium's role in meeting data center electricity needs.

Outlook is supported by structural demand trends, but high expense ratios and competition from pure-play uranium funds pose risks. The fund's performance hinges on uranium price movements and policy developments, with current technical weakness suggesting caution in the near term.